chufangao/CTO huggingface dataset:
Clinical trial NCT04573777: Reducing Intracranial atheroSclErosis With Repatha
Official title: Reducing Intracranial atheroSclErosis With Repatha
Acronym: RISER
Sponsor: University of California, Los Angeles (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Funding Discontinued
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-23
Primary completion date: 2021-12-16
Completion date: 2021-12-16
Plan to share individual participant data: NO
Clinical trial NCT03476239: Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Official title: An Open-label, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 121.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-18
Primary completion date: 2019-08-21
Completion date: 2021-04-08
Baseline population: Participants enrolled in the study who received at least 1 infusion of blinatumomab.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT05116969: A Phase 1 Study of PTX-35 in Healthy Volunteers
Official title: A Phase 1, Single Dose-Escalation and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous PTX-35 Adminsitration in Healthy Volunteers
Sponsor: Heat Biologics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor withdrew submission to Human Research Ethics Committee as it evaluates the need for healthy volunteer data for development plan.
Enrollment: 0.0 (ACTUAL)
Number of arms: 7.0
Start date: 2021-11-24
Primary completion date: 2022-11-29
Completion date: 2022-11-29
Clinical trial NCT05602727: Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
Official title: A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study To Evaluate The Safety And Efficacy Of MK-1942 As Adjunctive Therapy In Participants With Mild To Moderate Alzheimer's Disease Dementia
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Voluntarily terminated due to benefit/risk assessment
Enrollment: 99.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-12-02
Primary completion date: 2023-09-27
Completion date: 2023-09-27
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT01011777: Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence
Official title: Phase I Study of Endoscopically Injected Muscle Derived Cells in Participants With Exstrophy-epispadias Complex Related Urinary Incontinence
Acronym: MDC
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to participants withdrawal prior to anticipated end of study.
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-01
Primary completion date: 2020-01-23
Completion date: 2020-01-23
Clinical trial NCT05193370: Angiotensin II vs. Vasopressin in Septic Shock
Official title: A Randomized Controlled Pilot Trial of Angiotensin II Versus Vasopressin as Second-line Vasopressor in the Treatment of Septic Shock
Sponsor: University of New Mexico (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Funding and protocol changes. Replaced with new pilot trial.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-03
Primary completion date: 2022-11-30
Completion date: 2022-11-30
Plan to share individual participant data: NO
Clinical trial NCT04244825: Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF
Official title: A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects With Idiopathic Pulmonary Fibrosis
Sponsor: Blade Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Withdrawn due to concerns for patient safety during COVID-19 crisis
Enrollment: 0.0 (ACTUAL)
Number of arms: 8.0
Start date: 2019-12-15
Primary completion date: 2020-09-14
Completion date: 2020-11-05
Plan to share individual participant data: NO
Clinical trial NCT04538352: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
Official title: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With Type-2 Diabetes Mellitus (TRANSITION-T2D) A Prospective Randomized Controlled Trial
Acronym: TRANSITION-T2D
Sponsor: The Cleveland Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-18
Primary completion date: 2023-03-31
Completion date: 2023-11-01
Baseline population: Individual participants who were randomized to the two arms of the study
Plan to share individual participant data: NO
Clinical trial NCT05325164: Methadone for 'Adenocarcinopathic' Pain Treatment
Official title: Methadone for 'Adenocarcinopathic' Pain Treatment: Methadone vs. Morphine Vanguard RCT
Acronym: METHADOPT
Sponsor: Ottawa Hospital Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by new Sponsor/Investigator if it is started.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-30
Primary completion date: 2023-08-31
Completion date: 2023-09-30
Plan to share individual participant data: NO
Clinical trial NCT04912063: Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
Official title: A Phase 1b Dose Escalation Study of Lemzoparlimab in Combination With Venetoclax and/or Azacitidine in Subjects With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic considerations
Enrollment: 40.0 (ACTUAL)
Number of arms: 7.0
Start date: 2021-06-25
Primary completion date: 2023-05-09
Completion date: 2023-05-09
Plan to share individual participant data: NO
Clinical trial NCT02591615: Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
Official title: Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-small Cell Lung Cancer
Sponsor: Alliance Foundation Trials, LLC. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 91.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-03-31
Primary completion date: 2019-01-04
Completion date: 2020-07-04
Plan to share individual participant data: NO
Clinical trial NCT04749615: Does PAI Reduce Pain After TKA Among Knee Arthroplasty Patients Receiving ACB & IPACK?
Official title: Does Periarticular Injection (PAI) Reduce Pain After TKA Among Knee Arthroplasty Patients Receiving Adductor Canal Block and Infiltration Between the Popliteal Artery and the Capsule of the Posterior Knee (ACB&IPACK)? A Blinded, Randomized Controlled Trial.
Sponsor: Hospital for Special Surgery, New York (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 94.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-17
Primary completion date: 2022-04-01
Completion date: 2022-07-01
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in this article after de-identification (text, tables, figures, and appendices).
IPD time frame: Beginning 9 months and ending 36 months following article publication.
IPD access criteria: Investigators whose proposed use of the data has been approved by an Independent review committee (learned intermediary) identified for this purpose and who have signed a DUA.
Clinical trial NCT04083222: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx
Official title: A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously for 8 Weeks to Hypertensive Subjects With Uncontrolled Blood Pressure
Sponsor: Ionis Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 26.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-13
Primary completion date: 2020-07-20
Completion date: 2020-07-20
Baseline population: Safety set included all participants who were randomized and received at least 1 dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT01953692: A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)
Official title: A Phase Ib Multi-Cohort Trial of MK-3475 (Pembrolizumab) in Subjects With Hematologic Malignancies
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 197.0 (ACTUAL)
Number of arms: 9.0
Start date: 2013-11-22
Primary completion date: 2020-06-26
Completion date: 2020-06-26
Baseline population: All participants who received at least one dose of study treatment.
Limitations and caveats: Enrollment of participants into Cohort 5 of this study was discontinued after the Food and Drug Administration (FDA) implemented a clinical hold after determining the risks of pembrolizumab + lenalidomide outweighed any potential benefit.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03515707: Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
Official title: Autologous Transplant as Treatment for Favorable or Intermediate Risk MRD-Negative AML Patients After Initial Induction Therapy
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: PI recommended closure
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-10
Primary completion date: 2022-04-15
Completion date: 2022-07-30
Plan to share individual participant data: NO
Clinical trial NCT04421664: Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
Official title: Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Request of Health Canada after publication of https://doi.org/10.7326/M20-4207
Enrollment: 70.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-25
Primary completion date: 2020-08-17
Completion date: 2020-08-17
Plan to share individual participant data: YES
IPD sharing description: De-identified dataset will be included with publication.
IPD time frame: At time of publication
IPD access criteria: To be publicly provided
Clinical trial NCT04854499: Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Official title: A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Acronym: ELEVATE HNSCC
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision to terminate study
Enrollment: 193.0 (ACTUAL)
Number of arms: 8.0
Start date: 2021-09-07
Primary completion date: 2024-10-02
Completion date: 2024-10-02
Plan to share individual participant data: NO
Clinical trial NCT04329403: Clinical Endpoint Bioequivalence Study of Adapalene Gel 0.1%
Official title: Randomized, Double Blind, Placebo Controlled, Parallel Group Design, Three Arm, Multicentric Study to Evaluate the Efficacy and Safety of Topical Adapalene Gel, 0.1 % in Healthy Males and Nonpregnant Female Subjects With Acne Vulgaris
Sponsor: Aurobindo Pharma Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Market reasons
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-07-31
Primary completion date: 2021-01-31
Completion date: 2021-05-31
Clinical trial NCT04896541: Phase I Double-blind, Placebo-controlled Study of AZD7442
Official title: A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD7442 in Healthy Japanese Participants
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-16
Primary completion date: 2022-06-14
Completion date: 2022-06-14
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indeed that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04265534: KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
Official title: A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Acronym: KEAPSAKE
Sponsor: Calithera Biosciences, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of Clinical Benefit
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-24
Primary completion date: 2021-11-05
Completion date: 2022-02-09
Plan to share individual participant data: NO
Clinical trial NCT05564429: [18F]SF12051 for Imaging the 18-kDa Translocator Protein (TSPO) in Brain and Whole Body of Healthy Subjects
Official title: Assessment of [18F]SF12051 for Imaging the 18-kDa Translocator Protein (TSPO) in Brain and Whole Body of Healthy Subjects
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: due to futility
Enrollment: 10.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-02-02
Primary completion date: 2023-05-09
Completion date: 2024-01-30
Plan to share individual participant data: YES
IPD sharing description: .The results will be submitted to ClinicalTrials.gov
IPD time frame: 18 months after closure of protocol
IPD access criteria: BTRIS
Clinical trial NCT04379024: Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms
Official title: Pilot Study of Effects of Duavee® on Imaging and Blood Biomarkers In Women With Menopausal Symptoms at Increased Risk for Breast Cancer
Sponsor: University of Kansas Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Study agent no longer available
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-01
Primary completion date: 2021-07-30
Completion date: 2021-07-31
Plan to share individual participant data: NO
Clinical trial NCT02343679: Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies
Official title: A Phase II Study of the ALK Inhibitor, Ceritinib (LDK378), in Relapsed/Refractory ALK+ Hematologic Malignancies
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No accrual due to rarity of disease.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-05-31
Primary completion date: 2020-10-31
Completion date: 2022-10-31
Clinical trial NCT03811028: A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients
Official title: An Open, Single-arm, Multicenter Extension Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients
Sponsor: Swedish Orphan Biovitrum (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-19
Primary completion date: 2021-04-30
Completion date: 2021-05-07
Plan to share individual participant data: NO
Clinical trial NCT03169894: Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
Official title: Phase Ib Escalating Dose, Open-Label, Signal-Finding Study to Evaluate the Safety, Tolerability, and Short-Term Efficacy of the Anti-Light Monoclonal Antibody MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis Who Previously Failed Treatment With an Anti-TNFα Agent
Sponsor: Avalo Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic reasons
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-14
Primary completion date: 2021-09-14
Completion date: 2021-10-12
Baseline population: Safety Analysis Set
Limitations and caveats: This was an open label study, exploratory in nature, without a placebo control group, and as such, limits the interpretation of the study data.
Plan to share individual participant data: NO
Clinical trial NCT04730323: TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
Official title: TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
Sponsor: FMH College of Medicine and Dentistry (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 93.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-12
Primary completion date: 2020-06-12
Completion date: 2020-06-12
Plan to share individual participant data: YES
IPD sharing description: IPD can be shared with researchers in future too
IPD time frame: Whenever will be asked to, within few days
IPD access criteria: Only officials can access the data
Clinical trial NCT04164758: Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
Official title: A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
Sponsor: ACADIA Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study enrollment impacted by COVID-19 pandemic and Sponsor terminated for business reasons
Enrollment: 11.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-10-23
Primary completion date: 2020-09-25
Completion date: 2020-09-25
Baseline population: Randomized Analysis set, i.e. all randomized patients
Limitations and caveats: In March 2020, recruitment of new patients was paused due to the emerging coronavirus disease 2019 (COVID-19) pandemic. It was restarted in Jun 2020 and paused again in Aug 2020. Subsequently, no further patients were enrolled. On 24 Sep 2020, the sponsor decided to permanently stop the study.
Plan to share individual participant data: NO
Clinical trial NCT03992872: Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
Official title: A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines Versus Alphavirus Naïve Controls.
Acronym: WRAIR
Sponsor: Bavarian Nordic (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-20
Primary completion date: 2021-01-19
Completion date: 2021-01-19
Plan to share individual participant data: NO